These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9114912)

  • 1. The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man.
    Tham TC; McKaigue JP; Guy S; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1993 Sep; 36(3):251-6. PubMed ID: 9114912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.
    Tham TC; Guy S; McDermott BJ; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1995 Jul; 40(1):19-23. PubMed ID: 8527263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacodynamics of dilevalol.
    Riddell JG
    J Hum Hypertens; 1990 Jun; 4 Suppl 2():39-44. PubMed ID: 2370642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients.
    Walley T; Tsao Y; Scott A; Mackay E; Vandenburg M; Breckenridge A
    Br J Clin Pharmacol; 1993 Jun; 35(6):623-8. PubMed ID: 8329290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers.
    Riva E; Mennini T; Latini R
    Br J Pharmacol; 1991 Dec; 104(4):823-8. PubMed ID: 1687367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.
    Elliott HL; McLean K; Meredith PA; Sumner DJ; Reid JL
    Br J Clin Pharmacol; 1984 May; 17(5):565-72. PubMed ID: 6145440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine.
    Tomlinson B; Bompart F; Graham BR; Liu JB; Prichard BN
    Drugs; 1988; 36 Suppl 6():37-47. PubMed ID: 2908303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent alpha 1-adrenoceptor antagonist activity of the anti-arrhythmic drug, abanoquil (UK-52,046), without reduction in blood pressure in man.
    Tham TC; Guy S; Shanks RG; Harron DW
    Br J Clin Pharmacol; 1992 Apr; 33(4):405-9. PubMed ID: 1349492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects.
    Ferro A; Hall JA; Dickerson JE; Brown MJ
    Br J Clin Pharmacol; 1997 Mar; 43(3):301-8. PubMed ID: 9088585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
    Donnelly R; Macphee GJ
    Clin Pharmacokinet; 1991 Aug; 21(2):95-109. PubMed ID: 1884570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of adimolol, labetalol and propranolol on heart rate and blood pressure in man.
    Riddell JG; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1985 Apr; 19(4):405-10. PubMed ID: 2859871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug.
    Pringle TH; Deering AH; Scott MG; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1987 Apr; 23(4):411-23. PubMed ID: 2883988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta 2 agonist-mediated vasodilation and beta antagonism.
    Sybertz EJ; Watkins RW
    Am J Cardiol; 1989 Jun; 63(19):3I-6I. PubMed ID: 2567112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actions of dilevalol on adrenoceptors.
    Louis WJ; Drummer OH; Tung LH
    J Cardiovasc Pharmacol; 1988; 11 Suppl 2():S5-11. PubMed ID: 2464095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-adrenoceptor blockade by labetalol during long-term dosing.
    Semplicini A; Pessina AC; Rossi GP; Hlede M; Morandin F
    Clin Pharmacol Ther; 1983 Mar; 33(3):278-82. PubMed ID: 6130864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.
    Richards DA; Tuckman J; Prichard BN
    Br J Clin Pharmacol; 1976 Oct; 3(5):849-55. PubMed ID: 9968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in lymphocyte beta-adrenoceptor density after dilevalol oral treatment.
    Sbirrazzuoli V; Drici M; Garraffo R; Candito M; Gibelin P; Morand P; Lapalus P
    Drugs Exp Clin Res; 1989; 15(5):223-9. PubMed ID: 2551622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of dilevalol and propranolol on systemic and regional haemodynamics in healthy volunteers at rest and during exercise.
    Bellissant E; Annane D; Thuillez C; Giudicelli JF
    Eur J Clin Pharmacol; 1994; 47(1):39-47. PubMed ID: 7988622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological basis for antihypertensive effects of intravenous labetalol.
    Richards DA; Prichard BN; Boakes AJ; Tuckman J; Knight EJ
    Br Heart J; 1977 Jan; 39(1):99-106. PubMed ID: 12778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological effects of labetalol in man.
    Richards DA
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):721-3. PubMed ID: 10949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.